Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2‐chloro‐2′‐deoxyadenosine

• Published in: British journal of haematology Vol. 105; no. 1; pp. 268 - 270
• Main Authors: Van Den Neste, E., Louviaux, I., Michaux, J.‐L., Delannoy, A., Michaux, L., Hagemeijer, A., Scheiff, J.‐M., Bosly, A., Straetmans, N., Ferrant, A.
• Format: Journal Article
• Language: English
• Published: Oxford, U.K. and Cambridge, USA Blackwell Science Ltd 01-04-1999; Blackwell; Blackwell Publishing Ltd
• Subjects: 2‐chloro‐2′‐deoxyadenosine, cladribine, chronic lymphocytic leukaemia, secondary leukaemia, myelodysplastic syndrome; Adult; Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Chromosomes, Human, Pair 5 - genetics; Chromosomes, Human, Pair 7 - genetics; Cladribine - therapeutic use; Drug toxicity and drugs side effects treatment; Female; Hematology; Humans; Male; Medical sciences; Middle Aged; Miscellaneous (drug allergy, mutagens, teratogens...); Monosomy - genetics; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - genetics; Pharmacology. Drug treatments; Chromosomal aberration; Antineoplastic agent; Purine nucleoside; Toxicity; Aneuploidy; Myelodysplastic syndrome; Refractory anemia with excess blasts; Abnormal chromosome C7; Immunoglobulinopathy; Lymphoproliferative syndrome; Adult; Complication; Female; Waldenstrom macroglobulinemia; Monosomy; Human; Immunopathology; Malignant hemopathy; Non Hodgkin lymphoma; Case study; Chemotherapy; Treatment; Abnormal chromosome B5; Second cancer; Analog; Cladribine; Abnormal chromosome; Elderly
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/j.1365-2141.1999.01277.x

A few cases of secondary neoplasms occurring after treatment with 2‐chloro‐2′‐deoxyadenosine (2CdA) have been reported, mostly in patients previously exposed to other anti‐cancer drugs including alkylating agents (AA). Here we report on the occurrence of a myelodysplastic syndrome (MDS) with monosomy 5 and/or 7 in two patients after 2CdA treatment, without or prior to other toxic exposure. In light of a literature review and given the involvement of chromosomes frequently abnormal in secondary leukaemias, we suggest that 2CdA may induce therapy‐related MDS (t‐MDS).